Cleared Special

K183177 - Nitinol Thermocouple (TCN) Electrode

K183177 is the FDA 510(k) clearance for Nitinol Thermocouple (TCN) Electrode by Boston Scientific Corporation. It is a Class 2 Neurology device (product code GXI) cleared through the Special 510(k) pathway after a 112-day FDA review.

K183177 · Boston Scientific Corporation · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 2019
Decision
112d
Days
Class 2
Risk

K183177 is an FDA 510(k) clearance for the Nitinol Thermocouple (TCN) Electrode. Classified as Probe, Radiofrequency Lesion (product code GXI), Class II - Special Controls.

Submitted by Boston Scientific Corporation (Valencia, US). The FDA issued a Cleared decision on March 8, 2019 after a review of 112 days - within the typical 510(k) review window.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.4725 - the FDA neurology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Standard predicate reliance. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Boston Scientific Corporation devices

Submission Details

510(k) Number K183177 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 16, 2018
Decision Date March 08, 2019
Days to Decision 112 days
Submission Type Special
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
36d faster than avg
Panel avg: 148d · This submission: 112d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code GXI Probe, Radiofrequency Lesion
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.4725
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Peers - GXI Probe, Radiofrequency Lesion

All 30
Devices cleared under the same product code (GXI) and FDA review panel - the closest regulatory comparables to K183177.
Vesta RF Cannula
K190259 · Biomerics · Feb 2020
LCCS VC-S RF Cannula
K191293 · Lccs Products Limited · Jan 2020
Intracept Intraosseous Nerve Ablation System (RF Probe), Intracept Intraosseous Nerve Ablation System (Access Instruments), Relievant RF Generator
K190504 · Relievant Medsystems · May 2019
Rulo Radiofrequency Lesion Probe
K190256 · Epimed International, Inc. · Mar 2019
Intracept Intraosseous Nerve Ablation System (component Intracept RF Probe)
K180369 · Relievant Medsystems · Sep 2018
SMITH & NEPHEW RF CANNULATE
K090955 · Smith & Nephew, Inc. · Jul 2009